Acelrx pharmaceuticals announces it will not further revise its offer to acquire tetraphase

Acelrx pharmaceuticals announces it will not further revise its offer to acquire tetraphase.expects agreement to be terminated by tetraphase.acelrx will be paid a break-up fee of approximately $1.8 million.co-promotion agreement between acelrx and tetraphase remains in place.
ACRX Ratings Summary
ACRX Quant Ranking